Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program.

about

Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program.

Item

http://www.wikidata.org/entity/Q38744639

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Initial testing (stage 1) of t ...... c preclinical testing program.

@en

type

Item

label

Initial testing (stage 1) of t ...... c preclinical testing program.

@en

prefLabel

Initial testing (stage 1) of t ...... c preclinical testing program.

@en

P1476

Initial testing (stage 1) of t ...... ic preclinical testing program

@en

P2093

Andrei Gudkov

http://www.w3.org/2001/XMLSchema#string

Andrei Purmal

http://www.w3.org/2001/XMLSchema#string

Dias Kurmashev

http://www.w3.org/2001/XMLSchema#string

E Anders Kolb

http://www.w3.org/2001/XMLSchema#string

Hernan Carol

http://www.w3.org/2001/XMLSchema#string

Jianrong Wu

http://www.w3.org/2001/XMLSchema#string

John M Maris

http://www.w3.org/2001/XMLSchema#string

Peter J Houghton

http://www.w3.org/2001/XMLSchema#string

Raushan T Kurmasheva

http://www.w3.org/2001/XMLSchema#string

Stephen T Keir

http://www.w3.org/2001/XMLSchema#string

P2860

The chromatin-specific transcription elongation factor FACT comprises human SPT16 and SSRP1 proteins

Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma.

Interaction of FACT, SSRP1, and the high mobility group (HMG) domain of SSRP1 with DNA damaged by the anticancer drug cisplatin

Anti-malaria drug blocks proteotoxic stress response: anti-cancer implications.

National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing

Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer.

Signaling from p53 to NF-kappa B determines the chemotherapy responsiveness of neuroblastoma.

Expression of FACT in mammalian tissues suggests its role in maintaining of undifferentiated state of cells.

NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma.

Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer

P31

scholarly article

P356

10.1002/PBC.26263

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-09-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27650817

http://www.w3.org/2001/XMLSchema#string

P921

cbl-0137 free base

P932

5587189

http://www.w3.org/2001/XMLSchema#string